A survival game of hide and seek: Cytomegaloviruses and MHC class I antigen presentation pathways

Viral Immunology

Volumn 16, Issue 3, 2003, Pages 231-242

  Basta, Sameh ^a,b   Bennink, Jack R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VIRUS PROTEIN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CELL SUBPOPULATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; HERPES VIRUS; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; NONHUMAN; REVIEW; SURVIVAL; T LYMPHOCYTE; VIRUS CELL INTERACTION;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; DNA VIRUSES; HERPESVIRIDAE;

EID: 0141960095     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/088282403322396064     Document Type: Review

References (85)

1. Ahn, K., A. Angulo, P. Ghazal, et al. 1996. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc. Natl. Acad. Sci. U.S.A. 93:10990-10995.
2. Ahn, K., A. Gruhler, B. Galocha, et al. 1997. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 6:613-621.
3. Andrews, D.M., C.E. Andoniou, F. Granucci, et al. 2001. Infection of dendritic cells by murine cytomegalovirus induces functional paralysis. Nat. Immunol 2:1077-1084.
4. + T cells is regulated by virus-induced, soluble-mediator-dependent maturation of dendritic cells. J. Virol. 76:142-150.
5. + T cells by dendritic cells. J. Virol. 74:10018-10024.
6. + T cells. J. Immunol. 168:5403-5408.
7. Basta, S., S. Knoetig, A. Summerfield, et al. 2001. Lipopolysaccharide and phorbol 12-myristate 13-acetate both impair monocyte differentiation, relating cellular function to virus susceptibility. Immunology 103:488-497.
8. Basta, S., S.M. Knoetig, M. Spagnuolo-Weaver, et al. 1999. Modulation of monocytic cell activity and virus susceptibility during differentiation into macrophages. J. Immunol. 162:3961-3969.
9. Beersma, M.F., M.J. Bijlmakers, and H.L. Ploegh. 1993. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J. Immunol. 151:4455-4464.
10. Bennink, J.R. and J.W. Yewdell. 1990. Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr. Topics Microbiol. Immunol 163:153-184.
11. Biron, C.A., and L. Brossay. 2001. NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol 13:458-464.
12. Biron, C.A., K.S. Byron, and J.L. Sullivan. 1989. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320:1731-1735.
13. Browne, H., G. Smith, S. Beck, et al. 1990. A complex between the MHC class I homologue encoded by human cytomegalovirus and beta 2 microglobulin. Nature 347:770-772.
14. Bukowski, J.F., B.A. Woda, and R.M. Welsh. 1984. Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice. J. Virol. 52:119-128.
15. Cosman, D., J. Mullberg, C.L. Sutherland, et al. 2001. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123-133.
16. del Val, M., H. Hengel, H. Hacker, et al. 1992. Cytomegalovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment. J. Exp. Med. 176:729-738.
17. Diefenbach, A., and D.H. Raulet. 2001. Strategies for target cell recognition by natural killer cells. Immunol. Rev. 181:170-184.
18. Einsele, H., E. Roosnek, N. Rufer, et al. 2002. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99:3916-3922.
19. Fruh, K., A. Gruhler, R.M. Krishna, et al. 1999. A comparison of viral immune escape strategies targeting the MHC class I assembly pathway. Immunol. Rev. 168:157-166.
20. Gilbert, M.J., S.R. Riddell, B. Plachter, et al. 1996. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 383:720-722.
21. Gold, M.C., M.W. Munks, M. Wagner, et al. 2002. The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo. J. Immunol. 169:359-365.
22. Guidotti, L.G., K. Ando, M.V. Hobbs, et al. 1994. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 91:3764-3768.
23. Heath, W.R., and F.R. Carbone. 2001. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol 19:47-64.
24. Hengel, H., U. Reusch, G. Geginat, et al. 2000. Macrophages escape inhibition of major histocompatibility complex class I-dependent antigen presentation by cytomegalovirus. J. Virol. 74:7861-7868.
25. Holtappels, R., N.K. Grzimek, C.O. Simon, et al. 2002. Processing and presentation of murine cytomegalovirus pORFm164-derived peptide in fibroblasts in the face of all viral immunosubversive early gene functions. J. Virol. 76:6044-6053.
26. Holtappels, R., D. Thomas, J. Podlech, et al. 2000. The putative natural killer decoy early gene m04 (gp34) of murine cytomegalovirus encodes an antigenic peptide recognized by protective antiviral CD8 T cells. J. Virol. 74:1871-1884.
27. Jones, T.R., L.K. Hanson, L. Sun, et al. 1995. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J. Virol. 69:4830-4841.
28. Jones, T.R., E.J. Wiertz, L. Sun, et al. 1996. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc. Natl. Acad. Sci. U.S.A. 93:11327-11333.
29. + T cells by exogenous cell-associated antigens. Immunity 17:211-220.
30. Kageyama, S., T.J. Tsomides, Y. Sykulev, et al. 1995. Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J. Immunol. 154:567-576.
31. Kagi, D., B. Ledermann, K. Burki, et al. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31-37.
32. Kavanagh, D.G., and A.B. Hill. 2001. Evasion of cytotoxic T lymphocytes by murine cytomegalovirus. Semin. Immunol. 13:19-26.
33. Kavanagh, D.G., U.H. Koszinowski, and A.B. Hill. 2001. The murine cytomegalovirus immune evasion protein m4/gp34 forms biochemically distinct complexes with class I MHC at the cell surface and in a pre-Golgi compartment. J. Immunol. 167:3894-3902.
34. Khan, S., R. de Giuli, G. Schmidtke, et al. 2001. Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. J. Immunol. 167:4801-4804.
35. Kleijnen, M.F., J.B. Huppa, P. Lucin, et al. 1997. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J. 16:685-694.
36. + T cells and NK cells in vivo. Nat. Immunol. 3:529-535.
37. Kurts, C., M. Cannarile, I. Klebba, et al. 2001. Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo. J. Immunol. 166:1439-1442.
38. Loenen, W.A., C.A. Bruggeman, and E.J. Wiertz. 2001. Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. Semin. Immunol. 13:41-49.
39. LoPiccolo, D.M., M.C. Gold, D.G. Kavanagh, et al. 2003. Effective inhibition of K(b)- and D(b)-restricted antigen presentation in primary macrophages by murine cytomegalovirus. J.Virol. 77:301-308.
40. Machold, R.P., E.J. Wiertz, T.R. Jones, et al. 1997. The HCMV gene products US11 and US2 differ in their ability to attack allelic forms of murine major histocompatibility complex (MHC) class I heavy chains. J. Exp. Med. 185:363-366.
41. Margulies, D.H. 1997. Interactions of TCRs with MHC-peptide complexes: a quantitative basis for mechanistic models. Curr. Opin. Immunol. 9:390-395.
42. Mellman, I., and R.M. Steinman. 2001. Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255-258.
43. Mueller, S.N., C.M. Jones, C.M. Smith, et al. 2002. Rapid cytotoxic T lymphocyte activation occurs in the draining lymph nodes after cutaneous herpes simplex virus infection as a result of early antigen presentation and not the presence of virus. J. Exp. Med. 195:651-656.
44. + T cells by infected dendritic cells in vivo. Nat. Immunol. 3:265-271.
45. + T cells in vivo. J. Immunol. 166:4355-4362.
46. Norbury, C.C., and L.J. Sigal. 2003. Cross priming or direct priming: is that really the question? Curr. Opin. Immunol. 15:82-88.
47. Ochsenbein, A.F., and R.M. Zinkernagel. 2000. Natural antibodies and complement link innate and acquired immunity. Immunol. Today 21:624-630.
48. Orange, J.S., M.S. Fassett, L.A. Koopman, et al. 2002. Viral evasion of natural killer cells. Nat. Immunol. 3:1006-1012.
49. + T cells. Blood 100:3690-3697.
50. Pamer, E., and P. Cresswell. 1998. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16:323-358.
51. Polic, B., H. Hengel, A. Krmpotic, et al. 1998. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J. Exp. Med. 188:1047-1054.
52. Purbhoo, M.A., and M.M. Davis. 2003. Differential dynamics of CD8, TCR, and MHC at the immunological synapse. Presented at the Keystone Symposia: Cell Biology of the Immune Response, Keystone, Colorado.
53. Raftery, M.J., M. Schwab, S.M. Eibert, et al. 2001. Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity 15:997-1009.
54. Ramachandra, L., R. Song, and C.V. Harding. 1999. Phagosomes are fully competent antigen-processing organelles that mediate the formation of peptide:class II MHC complexes. J. Immunol. 162:3263-3272.
55. Ramirez, M.C., and L.J. Sigal. 2002. Macrophages and dendritic cells use the cytosolic pathway to rapidly cross-present antigen from live, vaccinia-infected cells. J. Immunol. 169:6733-6742.
56. Reddehase, M.J. 2002. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat. Rev. Immunol. 2:831-844.
57. Reddehase, M.J., F. Weiland, K. Munch, et al. 1985. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J. Virol. 55:264-273.
58. Reits, E.A., J.C. Vos, M. Gromme, et al. 2000. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 404:774-778.
59. Reusch, U., W. Muranyi, P. Lucin, et al. 1999. A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. EMBO J. 18:1081-1091.
60. Riddell, S.R., K.S. Watanabe, J.M. Goodrich, et al. 1992. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238-241.
61. Rock, K.L., I.A. York, T. Saric, et al. 2002. Protein degradation and the generation of MHC class I-presented peptides. Adv. Immunol 80:1-70.
62. Schubert, U., L.C. Anton, J. Gibbs, et al. 2000. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404:770-774.
63. + CTL following exposure to vaccinia virus via different routes. J. Immunol. 169:4222-4229.
64. Shresta, S., C.T. Pham, D.A. Thomas, et al. 1998. How do cytotoxic lymphocytes kill their targets? Curr. Opin. Immunol. 10:581-587.
65. Sigal, L.J., S. Crotty, R. Andino, et al. 1999. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398:77-80.
66. Sigal, L.J., and K.L. Rock. 2000. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP) -dependent and -independent pathways of antigen presentation. J. Exp. Med. 192:1143-1150.
67. Steffens, H.P., S. Kurz, R. Holtappels, et al. 1998. Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J. Virol. 72:1797-1804.
68. Sutherland, C.L., N.J. Chalupny, and D. Cosman. 2001. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions. Immunol. Rev. 181:185-192.
69. Sykulev, Y., M. Joo, I. Vturina, et al. 1996. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4:565-571.
70. Tabi, Z., M. Moutaftsi, and L.K. Borysiewicz. 2001. Human cytomegalovirus pp65- and immediate early 1 antigen-specific HLA class I-restricted cytotoxic T cell responses induced by cross-presentation of viral antigens. J. Immunol. 166:5695-5703.
71. + T cells. Nat. Med. 5:1039-1043.
72. + T cells clear influenza virus by perforin or Fas-dependent processes. J. Immunol. 159:5197-5200.
73. Tortorella, D., B.E. Gewurz, M.H. Furman, et al. 2000. Viral subversion of the immune system. Annu. Rev. Immunol. 18:861-926.
74. Wagner, M., A. Gutermann, J. Podlech, et al. 2002. Major histocompatibility complex class I allele-specific cooperative and competitive interactions between immune evasion proteins of cytomegalovirus. J. Exp. Med. 196:805-816.
75. Watts, C. 2001. Antigen processing in the endocytic compartment. Curr. Opin. Immunol. 13:26-31.
76. Wiertz, E.J., T.R. Jones, L. Sun, et al. 1996. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84:769-779.
77. Wiertz, E.J., D. Tortorella, M. Bogyo, et al. 1996. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384:432-438.
78. Yamashita, Y., K. Shimokata, S. Mizuno, et al. 1993. Down-regulation of the surface expression of class I MHC antigens by human cytomegalovirus. Virology 193:727-736.
79. Yewdell, J. 2002. To DRiP or not to DRiP: generating peptide ligands for MHC class I molecules from biosynthesized proteins. Mol. Immunol. 39:139-146.
80. Yewdell, J., L.C. Anton, I. Bacik, et al. 1999. Generating MHC class I ligands from viral gene products. Immunol. Rev. 172:97-108.
81. Yewdell, J.W., and J.R. Bennink. 1999. Mechanisms of viral interference with MHC class I antigen processing and presentation. Annu. Rev. Cell Dev. Biol. 15:579-606.
82. Yewdell, J.W., and J.R. Bennink. 2001. Cut and trim: generating MHC class I peptide ligands. Curr. Opin. Immunol. 13:13-18.
83. Yewdell, J.W., and A.B. Hill. 2002. Viral interference with antigen presentation. Nat. Immunol. 3:1019-1025.
84. Ziegler, H., R. Thale, P. Lucin, et al. 1997. A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity 6:57-66.
85. Zinkernagel, R.M. 2002. On cross-priming of MHC class I-specific CTL: rule or exception? Eur. J. Immunol. 32:2385-2392.